Merck ends a Phase 2 Alzheimer's trial for MK-1167, partnered with Neuphoria Therapeutics, after the drug missed efficacy criteria at an interim analysis.
Merck has axed a Phase 2 trial testing an experimental Alzheimer’s medicine, Endpoints News has learned.
The company terminated a mid-stage …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
On Monday, Praxis disclosed a late-stage failure for its investigational seizure medicine, and the company is pausing enrollment…
MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication…
